BRIEF-Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy Endpoints

Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX

0.00

June 22 (Reuters) - Definium Therapeutics Inc DFTX.O:

  • DEFINIUM THERAPEUTICS: POSITIVE TOPLINE RESULTS FROM PHASE 3 EMERGE STUDY OF DT120 ORALLY DISINTEGRATING TABLET (ODT) IN MAJOR DEPRESSIVE DISORDER

  • DEFINIUM THERAPEUTICS: STUDY OF DT120 ORALLY DISINTEGRATING TABLET MET PRIMARY ALL KEY SECONDARY EFFICACY ENDPOINTS

  • DEFINIUM THERAPEUTICS: DT120 ODT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS OR SUICIDALITY SIGNAL


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.